2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMORecruiting
The primary objective will be evaluating the difference in detection of new AF between the intervention practices (yearly 7 days AF screening with continuous heart rhythm monitoring) and control practices (care as usual) over three years of follow-…